Abstract
Tardive dyskinesia (TD) is a debilitating side-effect of antipsychotic treatment associated with reduced compliance and quality of life. TD prevalence is difficult to estimate accurately and is influenced by the increased use of antipsychotic drugs and the aging of the population. We assessed the prevalence, severity and characteristics of TD among schizophrenia patients at a university-affiliated psychiatric center in Israel. One hundred and twenty eight patients with schizophrenia were recruited and underwent demographic and clinical assessments. Subjects who met Schooler-Kane criteria for probable TD were compared to those without TD. Forty five subjects met probable TD criteria (prevalence: 35.2%; 95% CI 26.9% -44.1 %.). Subjects with TD were older and had a longer duration of treatment with antipsychotic medications. Diabetes mellitus, hypertension, head injuries and more severe psychiatric symptomatology did not predict TD. Patients in the TD-group had higher rates of extrapyramidal symptoms (EPS) and were more likely to receive an anticholinergic agent. The type of antipsychotic medication was not found to be associated with TD occurrence. Our findings confirm the established relationships between presence of TD and age, duration of antipsychotics treatment, anticholinergic treatment and the presence of EPS. Furthermore, our data support recent findings indicating that TD is still a prevalent disorder representing an unresolved public health issue.
Keywords: Aging, anticholinergic agents, atypical and typical antipsychotics, extrapyramidal side-effects, schizophrenia, Tardive dyskinesia.
Current Psychopharmacology
Title:Prevalence, Severity and Characteristics of Tardive Dyskinesia Among Schizophrenia Patients in an Israeli Psychiatric Center
Volume: 3
Author(s): Rony Sabbag, Bitya Fridman and Uriel Heresco-Levy
Affiliation:
Keywords: Aging, anticholinergic agents, atypical and typical antipsychotics, extrapyramidal side-effects, schizophrenia, Tardive dyskinesia.
Abstract: Tardive dyskinesia (TD) is a debilitating side-effect of antipsychotic treatment associated with reduced compliance and quality of life. TD prevalence is difficult to estimate accurately and is influenced by the increased use of antipsychotic drugs and the aging of the population. We assessed the prevalence, severity and characteristics of TD among schizophrenia patients at a university-affiliated psychiatric center in Israel. One hundred and twenty eight patients with schizophrenia were recruited and underwent demographic and clinical assessments. Subjects who met Schooler-Kane criteria for probable TD were compared to those without TD. Forty five subjects met probable TD criteria (prevalence: 35.2%; 95% CI 26.9% -44.1 %.). Subjects with TD were older and had a longer duration of treatment with antipsychotic medications. Diabetes mellitus, hypertension, head injuries and more severe psychiatric symptomatology did not predict TD. Patients in the TD-group had higher rates of extrapyramidal symptoms (EPS) and were more likely to receive an anticholinergic agent. The type of antipsychotic medication was not found to be associated with TD occurrence. Our findings confirm the established relationships between presence of TD and age, duration of antipsychotics treatment, anticholinergic treatment and the presence of EPS. Furthermore, our data support recent findings indicating that TD is still a prevalent disorder representing an unresolved public health issue.
Export Options
About this article
Cite this article as:
Sabbag Rony, Fridman Bitya and Heresco-Levy Uriel, Prevalence, Severity and Characteristics of Tardive Dyskinesia Among Schizophrenia Patients in an Israeli Psychiatric Center, Current Psychopharmacology 2014; 3 (1) . https://dx.doi.org/10.2174/2211556003666140319231741
DOI https://dx.doi.org/10.2174/2211556003666140319231741 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gene-Gene Interactions in a Context of Individual Variability in Antipsychotic Drug Pharmacogenomics
Current Pharmacogenomics and Personalized Medicine α7 Nicotinic Acetylcholine Receptor Mediated Neuroprotection in Parkinson’s Disease
Current Drug Targets Current Concepts in Gastric Motility in Diabetes Mellitus
Current Diabetes Reviews Current Therapeutic Options for Alzheimers Disease
Current Genomics Review of Recent Patents on Wearable Movement Sensors
Recent Patents on Biomedical Engineering (Discontinued) Cutting through the Complexities of mTOR for the Treatment of Stroke
Current Neurovascular Research Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Antipsychotic and Antiepileptic Drugs in Bipolar Disorder: The Importance of Therapeutic Drug Monitoring
Current Medicinal Chemistry The Role of Melatonin in Multiple Sclerosis, Huntington's Disease and Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets The Dopamine D3 Receptor: A Therapeutic Target for the Treatment of Neuropsychiatric Disorders
CNS & Neurological Disorders - Drug Targets Randomized Placebo-Controlled Trials of Omega-3 Polyunsaturated Fatty Acids in Psychiatric Disorders: A Review of the Current Literature
Current Drug Discovery Technologies How to Optimize the Effectiveness and Safety of Parkinson’s Disease Therapy? – A Systematic Review of Drugs Interactions with Food and Dietary Supplements
Current Neuropharmacology Current Drugs and Potential Future Neuroprotective Compounds for Parkinson’s Disease
Current Neuropharmacology Prospect of a Dopamine Contribution in the Next Generation of Antidepressant Drugs: The Triple Reuptake Inhibitors
Current Drug Targets Surgical Ventricular Restoration: An Operation To Reverse Remodeling - The Basic Science (Part I)
Current Cardiology Reviews Editorial (Thematic Issue: Novel Perspectives for Parkinson’s Disease Therapy: Insights from the Latest Advances in Disease Pathophysiology, Diagnostic and Experimental Tools and Molecular Targets)
CNS & Neurological Disorders - Drug Targets Is a "Mitochondrial Psychiatry" in the Future? A Review
Current Psychiatry Reviews Autism Spectrum Disorders: Etiology and Pharmacotherapy
Current Drug Therapy Gene Therapy for Neurological Disorders: Challenges and Future Prospects for the Use of Growth Factors for the Treatment of Parkinsons Disease
Current Gene Therapy Atypical Presentation of Tardive Dyskinesia Associated with Risperidone Long-Acting Injection as Maintenance Treatment in Bipolar Affective Disorder: A Case Report
Current Drug Safety